Interventional radiology technology developer Surefire Medical has raised $15 million in financing.
The round of Series C financing, led by Tullis Health Investors, will be used for a global launch of the new Surefire Precision, a device specifically designed to meet the clinical need for targeted delivery systems in the treatment of primary liver cancer.
KMG Capital Partners, Partisan Management Group, MCG Partners, High Country Ventures, and angel investors also participated in the financing.
